OpenAI and FDA Collaborate on AI-Driven Drug Evaluation Initiatives

According to an article published on Wednesday by Wired, OpenAI has met with representatives from the U.S. Food and Drug Administration (FDA) to explore the agency’s use of artificial intelligence to expedite drug evaluation processes.

The report highlights discussions surrounding a project named cderGPT, which appears to be an AI tool intended for the Center for Drug Evaluation and Research (CDER). This center oversees both prescription and over-the-counter medications in the U.S. It has also been reported that partners associated with Elon Musk’s DOGE were involved in these discussions.

Drug development processes often exceed a decade in duration. OpenAI’s collaboration with the FDA aims to hasten a portion of this timeline, particularly in the later stages, as stated by Wired. AI has long been promoted as a possible accelerant throughout the drug development lifecycle, enhancing some notoriously sluggish steps. However, unanswered questions remain regarding how to manage the unpredictability of AI models.